Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Takeda_Pharmaceutical_Company
January 2019 |
| gptkbp:awards |
Various industry awards
|
| gptkbp:CEO |
gptkb:Dr._Flemming_Ornskov
|
| gptkbp:clinicalTrials |
Ongoing studies for new therapies
|
| gptkbp:corporateSocialResponsibility |
Sustainability initiatives
Community engagement programs Employee volunteer programs Commitment to patient advocacy |
| gptkbp:employees |
over 23,000
|
| gptkbp:foundedIn |
1986
|
| gptkbp:globalPresence |
Operations in over 100 countries
|
| gptkbp:headquarteredIn |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire US Holdings
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
Specialty pharmaceuticals
|
| gptkbp:parentCompany |
gptkb:Takeda_Pharmaceutical_Company_Limited
|
| gptkbp:partnerships |
Various collaborations with biotech firms
|
| gptkbp:philanthropy |
Grants for educational programs
Funding for research initiatives Disaster relief contributions Support for health-related charities Support for rare disease organizations |
| gptkbp:products |
gptkb:Elaprase
gptkb:Fosrenol gptkb:Cinryze Adderall Cerezyme Intuniv Replagal Vyvanse Myalept Takhzyro Vpriv Firazyr Lanadelumab |
| gptkbp:regulatoryCompliance |
FDA_approved_products
EMA_approved_products |
| gptkbp:research_areas |
Gastroenterology
Genetics Immunology Neuroscience Oncology Endocrinology Hematology Rare diseases |
| gptkbp:researchAndDevelopment |
Significant investment
|
| gptkbp:revenue |
$15 billion (2017)
|
| gptkbp:specializesIn |
Rare diseases
|
| gptkbp:website |
www.shire.com
|